ClinicalTrials.gov record NCT07382128

Myocardial Perfusion CMR for Differentiating and Characterizing Hypertrophic Cardiomyopathy Phenotypes

Record copied from ClinicalTrials.gov: Oct 10, 2026AI summaries generated: Sep 17, 2026

About this page. This page shows the study's official ClinicalTrials.gov record ↗, with added help to make it easier to understand. We explain medical terms, highlight key details in plain language, and suggest questions you may want to ask the study team.

The record is periodically copied from ClinicalTrials.gov and may lag behind changes. AI summaries are checked by software, not a clinician.Read moreShow less

The official record is written by the study sponsor and published on ClinicalTrials.gov. It may not always reflect the latest changes. Before making any decisions, please confirm important information with the study team and your own healthcare team.

Where you see "AI summary", AI was used to create a plain-language explanation and software checked it against the source. It has not been reviewed by a clinician, so it may contain mistakes or leave out important details.

StatusRecruitingThe study is currently enrolling participants. Only the study team can say whether a particular person can join.

Study typeObservationalA study in which researchers do not assign participants to a treatment or other intervention. They observe or measure what happens, which may include study visits, tests, questionnaires or a review of medical records.

Age18 years old and older

SexAll

LocationItaly

AI summaryWhat this study is about, in plain languageShow ▾Hide ▴

AI-written from the registry record, not the study's own wording. May contain errors or omissions. Check the registry text on this page and the original record ↗ before acting on it.

This observational cohort study uses cardiac magnetic resonance (CMR) perfusion imaging to compare blood-flow and perfusion patterns in adults with hypertrophic-phenotype cardiomyopathies, including sarcomeric and non-sarcomeric HCM, Anderson-Fabry disease, and cardiac amyloidosis, plus first-degree relatives and genetic carriers. Quantitative and qualitative perfusion measures are collected at baseline and again after 36 months. The study aims to find distinctive perfusion signatures that could help differentiate diagnoses, support risk stratification, and better understand ischemia’s role in fibrosis, arrhythmias, and long-term outcomes.

What it is studying. The study is testing whether quantitative and qualitative CMR perfusion imaging shows different patterns of reduced blood flow or perfusion abnormalities across various hypertrophic cardiomyopathy phenotypes (including sarcomeric and non-sarcomeric HCM, Anderson-Fabry disease, and cardiac amyloidosis), and among first-degree relatives and genetic mutation carriers. Researchers will compare myocardial blood flow and perfusion patterns at baseline and after 36 months to look for distinctive signatures and to explore links between ischemia, fibrosis progression, arrhythmias, and clinical outcomes.

What the researchers hope to learn. To identify distinctive myocardial perfusion patterns for different hypertrophic-phenotype cardiomyopathies; to compare quantitative and qualitative perfusion defects at baseline and after 36 months; and to explore how ischemia may relate to fibrosis progression, arrhythmias, and long-term outcomes.

What this study is about

The study's own summary, as published on ClinicalTrials.gov. Underlined terms have a short explanation.

This observational study aims to evaluate myocardial perfusion abnormalities using quantitative and qualitative cardiac magnetic resonance (CMR) perfusion imaging in patients with hypertrophic cardiomyopathy (HCM) phenotypes, including sarcomeric and non-sarcomeric HCM, Anderson-Fabry disease (AFD), and cardiac amyloidosis. The study will also include first-degree relatives of affected patients and genetic mutation carriers. By comparing myocardial blood flow and perfusion patterns across these different conditions, the study seeks to identify distinctive perfusion signatures that may improve diagnostic differentiation, support risk stratification, and provide insights into the role of ischemia in fibrosis progression, arrhythmias, and long-term outcomes.

Eligibility

The criteria exactly as listed on ClinicalTrials.gov. Only the study team can say whether they apply to you.

Inclusion criteria

A confirmed diagnosis of cardiomyopathy with a hypertrophic phenotype, according to current ESC guidelines; or a first-degree relative of a patient with a confirmed diagnosis of cardiomyopathy with a hypertrophic phenotype; or a carrier of a genetic mutation for hypertrophic cardiomyopathy (carriers).
Patient with an indication to undergo cardiac magnetic resonance imaging (CMR) according to current ESC guidelines.
Age ≥ 18 years
Written informed consent obtained

Exclusion criteria

History of previous myocardial infarction or myocardial revascularization (coronary artery bypass grafting or percutaneous coronary angioplasty) and/or evidence of coronary stenosis ≥ 50% on coronary CT scan or invasive coronary angiography.

Study description and what participation involves

The registry record has no detailed description beyond the summary above.

AI summaryWhat participation may involve, in plain languageShow ▾Hide ▴

AI-written from the registry record, not the study's own wording. May contain errors or omissions. Check the registry text on this page and the original record ↗ before acting on it.

If you join, you will give written informed consent and have your medical history and clinical data reviewed. You will undergo cardiac magnetic resonance (CMR) perfusion imaging at baseline and again after 36 months. The study will use those CMR images to evaluate myocardial perfusion patterns. The registry does not list other study procedures.

How the study is structured. An observational cohort study. Participants undergo cardiac MRI perfusion imaging and related measurements at the start of the study and again at 36 months. No treatments are assigned by the study; researchers only collect and compare imaging and perfusion data across the different participant groups.

Questions you could ask

These questions are suggestions for a conversation with the study team or your own clinician, not advice.

This is an observational study, so the study itself gives no treatment. What would taking part involve for me, and would it change my usual care?
The listed sites are in Italy. Is any of them reachable for me, and does the study help with travel?
Which of the eligibility criteria would need to be checked with tests before I could join?

More on wild-type ATTR amyloidosis

This trial is also listed on this site under ATTRv amyloidosis and Fabry disease.

Clinical trials121 trials listed for wild-type ATTR amyloidosisEvery trial the registry lists for wild-type ATTR amyloidosis, with recruitment status, phase and sites, updated from ClinicalTrials.gov.See all trials →Research updatesWhat changed in wild-type ATTR amyloidosis researchLatest monthly update: September 2026. Includes: Frailty and support needs. New research summarized each month in plain language, with links to every source paper.Read the latest update →

Important dates

Study start: Jun 1, 2025
Primary completion: Jun 1, 2027 (estimated)
Study completion: Jun 1, 2027 (estimated)
Target enrollment: 250 participants (estimated)
Last updated on registry: Feb 2, 2026
Data verified: Oct 10, 2026

Sponsor and research team

The lead sponsor funds and oversees the trial. A pharmaceutical or biotech company sponsor typically means the study is testing that company's drug or device; a hospital, university, or government agency usually indicates investigator-initiated or publicly funded research.

Lead sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna

Central study contact

If you're interested in participating, the central contact can answer general questions about the study — including eligibility requirements and how to find a recruiting site near you. Actual eligibility is determined by the site's medical team.

Luigi Lovato 📞 +390512144740 ✉ luigi.lovato@aosp.bo.it

Participating sites (1)

IRCCS Azienda Ospedaliero-Universitaria di BolognaRecruiting
Bologna, BO, 40124 · Italy
- Luigi Lovato · +390512144740

Terms used on this page · explanations by MedicalUpdates.ai

magnetic resonance imaging: A scan that uses magnets and radio waves, not X-rays, to make detailed pictures of the inside of the body. Some implants and metal objects mean a person cannot have one.
Written informed consent: The process of explaining a study, including its risks and what participation involves, so that a person can decide freely whether to take part. Consent is usually documented in writing, and a participant can choose to leave the study later.
CT scan: An X-ray scan that builds detailed cross-section images of the body. 'High-resolution' CT (HRCT) is used to look closely at the lungs.
Inclusion Criteria: The conditions a person must meet to be considered for the study, for example a confirmed diagnosis, an age range or a test result.
Exclusion Criteria: The conditions that rule a person out even if they meet the inclusion criteria, for example other illnesses, certain medicines or pregnancy.

The study record on this page is reproduced from ClinicalTrials.gov, a database of the U.S. National Library of Medicine, where it was submitted by the study sponsor. MedicalUpdates.ai does not own this content, is not affiliated with or endorsed by ClinicalTrials.gov, NIH, or the U.S. Government, and does not verify the record. Plain-language notes, the glossary and the questions above are added by this site; text in the boxes marked "AI summary" was written by an AI model and may contain errors. Registry records change over time. Check the original record for the current version and discuss eligibility or participation with a qualified healthcare professional.

← Back to clinical trials